745 related articles for article (PubMed ID: 25179482)
1. New oral anticoagulants for the prevention of thromboembolic complications in atrial fibrillation: a single centre experience.
Gorczyca-Michta I; Wożakowska-Kapłon B
Kardiol Pol; 2015; 73(2):85-93. PubMed ID: 25179482
[TBL] [Abstract][Full Text] [Related]
2. Therapy persistence in newly diagnosed non-valvular atrial fibrillation treated with warfarin or NOAC. A cohort study.
Martinez C; Katholing A; Wallenhorst C; Freedman SB
Thromb Haemost; 2016 Jan; 115(1):31-9. PubMed ID: 26246112
[TBL] [Abstract][Full Text] [Related]
3. Is the prescription right? A review of non-vitamin K antagonist anticoagulant (NOAC) prescriptions in patients with non-valvular atrial fibrillation. Safe prescribing in atrial fibrillation and evaluation of non-vitamin K oral anticoagulants in stroke prevention (SAFE-NOACS) group.
Pharithi RB; Ranganathan D; O'Brien J; Egom EE; Burke C; Ryan D; McAuliffe C; Vaughan M; Coughlan T; Morrissey E; McHugh J; Moore D; Collins R
Ir J Med Sci; 2019 Feb; 188(1):101-108. PubMed ID: 29860595
[TBL] [Abstract][Full Text] [Related]
4. Selection, management, and outcome of vitamin K antagonist-treated patients with atrial fibrillation not switched to novel oral anticoagulants. Results from the Dresden NOAC registry.
Michalski F; Tittl L; Werth S; Hänsel U; Pannach S; Sahin K; Weiss N; Beyer-Westendorf J
Thromb Haemost; 2015 Nov; 114(5):1076-84. PubMed ID: 25994496
[TBL] [Abstract][Full Text] [Related]
5. Choice of New Oral Anticoagulant Agents Versus Vitamin K Antagonists in Atrial Fibrillation: FANTASIIA Study.
Moreno-Arribas J; Bertomeu-González V; Anguita-Sanchez M; Cequier Á; Muñiz J; Castillo J; Sanchis J; Roldán I; Marín F; Bertomeu-Martínez V;
J Cardiovasc Pharmacol Ther; 2016 Mar; 21(2):150-6. PubMed ID: 26229096
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
[TBL] [Abstract][Full Text] [Related]
7. Non-vitamin K antagonist oral anticoagulants in atrial fibrillation accompanying mitral stenosis: the concept for a trial.
De Caterina R; John Camm A
Europace; 2016 Jan; 18(1):6-11. PubMed ID: 26450845
[TBL] [Abstract][Full Text] [Related]
8. Shifting from vitamin K antagonists to non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: predictors, patterns and temporal trends.
Shiyovich A; Shalev V; Chodick G; Tirosh M; Katz A; Klar MM; Shuvy M; Pereg D; Minha S
BMC Cardiovasc Disord; 2021 Oct; 21(1):493. PubMed ID: 34645389
[TBL] [Abstract][Full Text] [Related]
9. Anticoagulant Treatment in Patients with AF and Very High Thromboembolic Risk in the Era before and after the Introduction of NOAC: Observation at a Polish Reference Centre.
Bielecka B; Gorczyca-Głowacka I; Ciba-Stemplewska A; Wożakowska-Kapłon B
Int J Environ Res Public Health; 2023 Jun; 20(12):. PubMed ID: 37372735
[TBL] [Abstract][Full Text] [Related]
10. Changes in Oral Anticoagulation Therapy over One Year in 51,000 Atrial Fibrillation Patients at Risk for Stroke: A Practice-Derived Study.
Hohnloser SH; Basic E; Nabauer M
Thromb Haemost; 2019 Jun; 119(6):882-893. PubMed ID: 30900220
[TBL] [Abstract][Full Text] [Related]
11. Oral anticoagulation therapy use in patients with atrial fibrillation after the introduction of non-vitamin K antagonist oral anticoagulants: findings from the French healthcare databases, 2011-2016.
Maura G; Billionnet C; Drouin J; Weill A; Neumann A; Pariente A
BMJ Open; 2019 Apr; 9(4):e026645. PubMed ID: 31005934
[TBL] [Abstract][Full Text] [Related]
12. Use of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients: insights from a specialist atrial fibrillation clinic.
Lee SI; Sayers M; Lip GY; Lane DA
Int J Clin Pract; 2015 Nov; 69(11):1341-8. PubMed ID: 26234557
[TBL] [Abstract][Full Text] [Related]
13. Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF).
Rohla M; Weiss TW; Pecen L; Patti G; Siller-Matula JM; Schnabel RB; Schilling R; Kotecha D; Lucerna M; Huber K; De Caterina R; Kirchhof P
BMJ Open; 2019 Mar; 9(3):e022478. PubMed ID: 30928922
[TBL] [Abstract][Full Text] [Related]
14. Recanalization therapies in acute ischemic stroke patients: impact of prior treatment with novel oral anticoagulants on bleeding complications and outcome.
Seiffge DJ; Hooff RJ; Nolte CH; Béjot Y; Turc G; Ikenberg B; Berge E; Persike M; Dequatre-Ponchelle N; Strbian D; Pfeilschifter W; Zini A; Tveiten A; Næss H; Michel P; Sztajzel R; Luft A; Gensicke H; Traenka C; Hert L; Scheitz JF; De Marchis GM; Bonati LH; Peters N; Charidimou A; Werring DJ; Palm F; Reinhard M; Niesen WD; Nagao T; Pezzini A; Caso V; Nederkoorn PJ; Kägi G; von Hessling A; Padjen V; Cordonnier C; Erdur H; Lyrer PA; Brouns R; Steiner T; Tatlisumak T; Engelter ST;
Circulation; 2015 Sep; 132(13):1261-9. PubMed ID: 26232277
[TBL] [Abstract][Full Text] [Related]
15. Comparison of clinical characteristics of real-life atrial fibrillation patients treated with vitamin K antagonists, dabigatran, and rivaroxaban: results from the CRAFT study.
Balsam P; Ozierański K; Tymińska A; Żukowska K; Zaleska M; Szepietowska K; Maciejewski K; Peller M; Grabowski M; Lodziński P; Praska-Ogińska A; Zaboyska I; Kołtowski Ł; Kowalczuk A; Bednarski J; Filipiak KJ; Opolski G
Kardiol Pol; 2018; 76(5):889-898. PubMed ID: 29350386
[TBL] [Abstract][Full Text] [Related]
16. New oral anti-coagulants versus vitamin K antagonists in high thromboembolic risk patients.
Bellin A; Berto P; Themistoclakis S; Chandak A; Giusti P; Cavalli G; Bakshi S; Tessarin M; Deambrosis P; Chinellato A
PLoS One; 2019; 14(10):e0222762. PubMed ID: 31589620
[TBL] [Abstract][Full Text] [Related]
17. The Changing Landscape for Stroke Prevention in AF: Findings From the GLORIA-AF Registry Phase 2.
Huisman MV; Rothman KJ; Paquette M; Teutsch C; Diener HC; Dubner SJ; Halperin JL; Ma CS; Zint K; Elsaesser A; Bartels DB; Lip GY;
J Am Coll Cardiol; 2017 Feb; 69(7):777-785. PubMed ID: 28209218
[TBL] [Abstract][Full Text] [Related]
18. Differences in knowledge among patients with atrial fibrillation receiving non-vitamin K antagonist oral anticoagulants and vitamin K antagonists.
Konieczyńska M; Sobieraj E; Bryk AH; Dębski M; Polak M; Podolec P; Małecka B; Pająk A; Desteghe L; Heidbuchel H; Undas A
Kardiol Pol; 2018; 76(7):1089-1096. PubMed ID: 29528483
[TBL] [Abstract][Full Text] [Related]
19. Minimally interrupted novel oral anticoagulant versus uninterrupted vitamin K antagonist during atrial fibrillation ablation.
De Heide J; Vroegh CJ; Bhagwandien RE; Wijchers SA; Szili-Torok T; Zijlstra F; Lenzen MJ; Yap SC
J Interv Card Electrophysiol; 2018 Dec; 53(3):341-346. PubMed ID: 30074120
[TBL] [Abstract][Full Text] [Related]
20. Decision making for oral anticoagulants in atrial fibrillation: the ATA-AF study.
Gussoni G; Di Pasquale G; Vescovo G; Gulizia M; Mathieu G; Scherillo M; Panuccio D; Lucci D; Nozzoli C; Fabbri G; Colombo F; Riva L; Baldo CI; Maggioni AP; Mazzone A;
Eur J Intern Med; 2013 Jun; 24(4):324-32. PubMed ID: 23684591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]